LUND, SWEDEN--(Marketwire - February 11, 2010) -
Laquinimod -- Phase III program proceeding according to plan
57-57 -- exploratory clinical trial in progress
RhuDex™ -- additional preclinical studies to be conducted in 2010
ANYARA -- Phase III trials proceeding according to plan
TASQ -- primary endpoint met in clinical Phase II
ISI -- project proceeding according to plan
Net sales of SEK 10.8 M (53.5)
Operating loss of SEK 219.6 M (loss: 184.6)
Loss after tax of SEK 224.0 M (loss: 181.6)
Loss per share for the period amounted to SEK 3.81 (loss: 3.66)
For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46-19 20 95 Göran Forsberg VP Investor Relations & Business Development Tel: +46 (0)46-19 11 54 Hans Kolam CFO Tel: +46 (0)46-19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, 220 07 Lund Tel: +46 (0)46-19 20 00 Fax +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
Active Biotech AB Year-end Report, January-December 2009:
http://hugin.info/1002/R/1383189/341980.pdf
